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An overview of cytokine biosensing is provided, with a focus on the
opportunities provided by organic electronic platforms for monitoring these
inflammation biomarkers which manifest at ultralow concentration levels in
physiopathological conditions. Specifically, two of the field’s state-of-the-art
technologies—organic electrochemical transistors (OECTs) and electrolyte
gated organic field effect transistors (EGOFETs)—and their use in sensing
cytokines and other proteins associated with inflammation are a particular
focus. The overview will include an introduction to current clinical and “gold
standard” quantification techniques and their limitations in terms of cost,
time, and required infrastructure. A critical review of recent progress with
OECT- and EGOFET-based protein biosensors is presented, alongside a
discussion onthe future of these technologies in the years and decades ahead.
This is especially timely as the world grapples with limited healthcare
diagnostics during the Coronavirus disease (COVID-19)pandemic where one
of the worst-case scenarios for patients is the “cytokine storm.” Clearly,
low-cost point-of-care technologies provided by OECTs and EGOFETs can
ease the global burden on healthcare systems and support professionals by
providing unprecedented wealth of data that can help to monitor disease
progression in real time.
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Complex organisms, from plants to pri-
mates, require a well-developed specific
protective capacity to counteract noxious
stimuli such as pathogen invasion, tissue
damage,[1,2] and other kinds of hazard.[3]
The initial host response triggered by these
stimuli in vertebrates is inflammation,
which is a localized dynamic process involv-
ing blood components, more specifically
leukocytes and plasma proteins, together
with tissue cells. Its purpose is not only to
eliminate the harmful agents but also to fa-
cilitate repairing processes.
The inflammatory process involves four
components: i) inflammatory inducers, the
aforementioned harmful agents that trig-
ger the inflammatory response; ii) sensors,
such as macrophages, mast cells, and den-
dritic cells, which stimulate the produc-
tion of chemical mediators in response
to inducers; iii) mediators, among them
cytokines, which are cell-to-cell messen-
gers that primarily act locally at the target
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Figure 1. Inflammatory pathways. a) A pathological, physical, chemical, or other harmful trigger initiates a response from the body’s immune system,
b) comprising mast cells, dendritic cells, macrophages, and monocytes, among others. These immune cells release immune response compounds
(cytokines, chemokines) which have (c) downstream effects on, e.g., the vascular system, fever response, or organ function.
tissue with very fast response; and iv) target tissues, where me-
diators elicit the inflammatory response until neutralizing the
noxious stimuli.[2–4] The interplay between the main actors in in-
flammation is illustrated in Figure 1. The inflammatory response
takes place within minutes, and can last as long as several days,
until the noxious condition has been eliminated and the tissue
has been repaired. This process is known as the acute inflamma-
tory response, which is controlled and self-limited through the
activation of anti-inflammatory mechanisms in order to maintain
tissue homeostasis.
When the acute inflammatory response fails and noxious stim-
uli remain, inflammation persists, and becomes chronic. This
condition lasts from days to years, and can be local, confined
to the site of the acute response, or systemic, affecting large
parts of (or the entire) body.[3,5] Chronic inflammation is associ-
ated with a wide range of pathologies, including atherosclerosis,
cancer,[6] neurodegenerative diseases,[7,8] and obesity,[9,10] while
acute inflammation is associated with sepsis, human immun-
odeficiency virus (HIV) infection,[11] and many others, includ-
ing Coronavirus disease (COVID-19).[2,4,12] Systemic chronic low-
grade inflammation is characterized by a subclinical increase in
inflammatory parameters and has been linked to specific social,
environmental, and lifestyle factors, such as exposure to indus-
trial toxins, high-calorie diet, and physical inactivity, among oth-
ers. However, this condition can be observed even in the absence
of evident signs and symptoms of inflammation, for instance, in
elderly subjects experiencing “successful aging” (aging without
comorbidities).[13–15] Consequently, significant efforts have been
devoted to investigating the correlation between the onset of dif-
ferent pathologies and inflammation-related biomarkers, among
which acute-phase proteins (e.g., C-reactive protein, CRP) and cy-
tokines are possibly the most relevant. High levels of inflamma-
tory biomarkers have been associated with disease risk, progres-
sion, and adverse prognosis. Although some molecules, such as
CRP, are routinely used in clinical settings for diagnostic pur-
poses, it is worth mentioning the importance of the analysis of
several biomarkers, ideally simultaneously, in order to obtain a
characteristic disease “fingerprint” as well as to improve disease
prognosis, since a set of biomarkers can give more accurate in-
formation than a single one.[8,12]
Chemical mediators of inflammation include cytokines, a het-
erogenous group of polypeptides, proteins, and glycoproteins,
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which mediate cell signaling and communication among cells of
the immune system as well as between immune cells and other
tissues and organs. Cytokines comprise monomers, dimers, or
trimers, as in the case for tumor necrosis factor-alpha (TNF-
𝛼). Briefly, in response to noxious stimuli, a subset of cytokines
called proinflammatory cytokines is secreted by different cell
types, e.g., activated monocytes/macrophages, T helper cells,
and mast cells, in order to elicit inflammation and to recruit
and activate innate immune cells in the tissue of residence.
When secreted in low amounts, proinflammatory cytokines act
locally. If secreted in much larger amounts, cytokine “spillover”
from inflamed tissue to the circulatory system can occur. As a
consequence, the levels of circulating cytokines, which lie in the
picomolar range under physiological conditions, are increased by
up to a 1000-fold during the inflammatory response.[3,16,17]
A given cytokine function is heavily dependent on both the tar-
get tissue and the stimuli and therefore each cytokine can be in-
volved in a wide range of pathways that lead to diverse effects due
to their multiple biological properties. This feature is known as
pleiotropy and is a hallmark of cytokines.[17] Therefore, cytokine
upregulation has been associated with many diseases, both as a
cause and as an effect. This is one of the primary reasons why cy-
tokines have received so much attention in recent years for dis-
ease diagnosis, prognosis, and therapy monitoring for a range
of pathologies. In addition to the general diseases related to in-
flammation (mentioned above), pathologies specifically associ-
ated with cytokine upregulation include atherosclerosis,[18] heart
failure,[19] cancer,[20] rheumatoid arthritis,[21] psoriasis, and sys-
temic sclerosis.[22]
Another hallmark of cytokines is how they work as a network
of interacting compounds in a concerted immune response.[16]
A recent computational model, immuneXpresso (iX), was built
to perform a meta-analysis in order to obtain an immune pro-
file associated with each disease including the specific cytokine
profile.[23] The software analyzed literature in PubMed, by sur-
veying the intercellular interactions involving cytokines and their
association with disease development. The study identified a sub-
set of cytokines that regularly appeared as highly active in the
network, including TNF-𝛼, IL-6, tumor growth factor-𝛽 (TGF-𝛽),
and interferon-𝛾 (IFN-𝛾). Additional analysis of cytokine profiles
in 188 diseases resulted in a group of “backbone cytokines” which
were found to be common to most of the diseases in the study.
These findings highlight the importance of using cytokine profil-
ing, rather than individual cytokines, as inflammatory-associated
disease biomarkers that could be used to monitor a wide array of
diseases.
With the recent coronavirus pandemic, the “cytokine storm”—
the sudden uncontrolled secretion of several kinds of cytokines
in response to infectious and noninfectious diseases—has en-
tered the public discourse.[16,24] In the cytokine storm, the in-
flammation moves from local to systemic via the circulation, re-
sulting in a high increase of cytokine levels in the blood (i.e.,
spillover). It has been observed that some people are more sus-
ceptible to the cytokine storm than others, developing a more se-
vere clinical condition, although the molecular mechanism un-
derlying this difference is not yet clear. Cytokine storm syndrome
could even mimic sepsis symptomatology, leading to death in se-
vere cases. The term “cytokine storm” started to appear more
frequently in scientific reports from the early 2000s, especially
in relation to viral diseases including the severe acute respira-
tory syndrome coronavirus (SARS-CoV) infection.[24] Studies per-
formed in the years following the SARS epidemic (2002), showed
the role of cytokines in the pathogenesis—especially in the crit-
ical phase of the disease—in which severe symptoms seemed to
be associated with a cytokine storm. This symptomatology corre-
sponded to lung damage with rupture of pulmonary alveoli caus-
ing inefficient oxygenation, and thus the “acute respiratory dis-
tress syndrome,” all as a consequence of the excessive release
of cytokines.[25,26] The recent pandemic situation of COVID-19,
caused by the coronavirus SARS-Cov-2, has rekindled attention
on the important role of cytokines in the evolution of the dis-
ease, and highlighted the use of inflammatory cytokines as dis-
ease biomarkers. Several studies have found a strong correlation
between unfavorable prognosis of COVID-19 with high levels of
inflammatory cytokines,[27] especially with IL-6 and CRP.[28–32]
Furthermore, taking into consideration the short half-life of cy-
tokines, and that some diseases display an acute onset (as with
COVID-19), development of fast, accurate, and reliable cytokine
biosensors has emerged as an imperative need for point-of-care
(PoC) testing.[33]
During the last couple of decades, the number of studies fo-
cusing on cytokines as disease biomarkers has increased consid-
erably, thus driving significant advances in various biosensing
technologies. Those biosensors are needed not only for diagno-
sis but also for monitoring the treatment of diseases. The above-
mentioned features define the necessary requisites and figures-
of-merit for cytokine biosensors: i) ultralow limit of detection
(LOD) and high sensitivity, since cytokines are present at very
low concentrations (sub-pm) under physiological conditions; ii)
wide dynamic range, spanning pm to nm concentrations and be-
yond, as cytokines levels can reach a 1000-fold increase under
pathological conditions; iii) simultaneous detection of a set of cy-
tokines, to monitor changes in the expression at a network level,
and allowing for detection of altered balance between pro- and
anti-inflammatory cytokines; iv) fast response, especially in those
cases where an acute onset is observed, and v) easy implementa-
tion at the PoC for disease diagnosis and monitoring. In addi-
tion, manufacturing biosensors with features such as low power
consumptions, ease of use, real-time read-out, low-cost, and dis-
posability would be beneficial for large-scale implementation and
distribution. In the current COVID-19 pandemic, reliable biosen-
sors for screening positive cases have come to the forefront as a
potentially game-changing tool to fight the spread of the virus.
Biosensors with these characteristics will be useful, not only in
this current situation, but also in future outbreaks, and are thus
now one of the major focuses of the research community.
2. State-of-the-Art in Cytokine Sensing
Biosensors are devices for specific analyte detection, providing
an output signal that correlates to analyte concentration. A
biosensor is composed by: i) a biorecognition element (typically
an antibody, aptamer, or an enzyme), which detects and binds
specifically the analyte; ii) a transducer that converts a physical or
chemical change (typically, a binding event or an enzymatic reac-
tion) into a measurable signal (the main transducers being elec-
trochemical, optical, piezoelectric, thermometric, and magnetic);
iii) the read-out, which is the processed and displayed signal
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Figure 2. Schematics of a label-free biosensor.
(Figure 2).[34,35] Clearly, both the specific biorecognition element
and the transducing strategy affect the biosensor figures of merit,
selectivity, sensitivity, and dynamic range of detection above all.
Antibodies (Abs) have been (and still are) by far the most
widely employed biorecognition element in biosensing. Nev-
ertheless, in the last two decades significant efforts have been
put to seek for alternative binders, in order to overcome the
main limitations connected with the use of Abs, namely their
complex synthesis procedure, the unknown sequence and their
large dimensions, which might represent a severe limitation
in some electrochemical or electrical sensing schemes, as the
binding event would take place well beyond the Debye length,
thus hampering the device sensitivity. Nonimmunoglobulin-
based scaffold are emerging as substitutes for the Abs in
both theragnostic and diagnostics. They can be subdivided in
DNA/RNA aptamers and peptide aptamers. The former are
synthetic oligonucleotides, specifically generated and selected
in vitro through a process called systemic evolution of ligands
by exponential enrichment.[36] Peptide aptamers are based on
relatively small, structurally robust proteins as scaffold (like pro-
teases), with connecting loops that make them highly selective
for protein recognition.[37,38] These engineered scaffolds present
high affinity and specificity, low-cost production, and small size,
which also confers them long-term storage stability. Moreover,
the high control on their sequence and the facile synthesis
allow the design of ad hoc modifications, such as the insertion of
linkers or functional groups, that would enable controlled immo-
bilization on a surface.[39] As will be clear from the next sections,
both immunoglobulin- and nonimmunoglobulin-based binders
have been employed for label free cytokine detection.
Enzyme-linked immunosorbent assay (ELISA) is a quantita-
tive biochemical technique which relies on antibody-antigen in-
teraction and colorimetric reaction to measure specific analyte.
This assay remains the “gold standard” technology for cytokines
detection and quantification, with a very high sensitivity in the
sub pg mL−1 range of concentration for cytokines such as IL-
6 (LOD of 0.09 pg mL−1).[40] ELISA is used for detection of a
single analyte; however, as highlighted in the previous section,
when it comes to cytokines, a simultaneous detection of multiple
biomarkers is preferred. Flow cytometry-based technology (e.g.,
Luminex) exploits laser beam and fluorescent labeled Abs flowing
down a chamber for the detection of biomarkers and cells. This
technique has emerged to overcome the limitation of detecting
single molecule, being widely used in research and clinics with
similar sensitivity as ELISA, detecting on the sub pg mL−1 range
of concentration (LOD of 0.2 pg mL−1 for IL-6).[41] Both commer-
cial techniques are highly sensitive and selective, but they present
some limitations: first of all, both are time consuming, the whole
process taking 3–8 h.[42] ELISA requires relatively larger sample
volumes (50–100 μL per sample), while Luminex requires only
25–50 μL for multiple samples, but both need specialized equip-
ment and personnel, as well as fluorescent labeling for detection.
Therefore, efforts have been put to overcome all these limitations,
in search for a technique that could also be implemented at the
PoC, facilitating the transition from the benchtop to the clinics.
Novel biosensing strategies have been developed during the last
20 years, and have been widely reviewed.[42–45] The scope of this
section is to provide an overview of the most recent (i.e., within
the last 5 years) advances in cytokine detection, with a focus on
label-free techniques. In particular, for this progress report, we
define as “labels” foreign molecules that need to be added prior
or after the incubation of the analyte with the sensing unit. In
what follows, we classify and briefly describe the most recently
demonstrated label free cytokine biosensors classified based on
the transducer principle and close the present section with some
comments regarding the necessary requisites that novel sensing
platforms should feature to fill the gap between laboratory-scale
research and implementation at the PoC.
2.1. Optical Biosensors
Label free devices based on optical transduction exploit the in-
teraction between light and the sensing element immobilized on
the surface. When the biorecognition unit binds the analyte, one
of the properties (e.g., phase or intensity) of the light, that is re-
flected at the sensing interface, changes in a way that is propor-
tional to the amount of adsorbed analyte. Surface plasmon res-
onance (SPR) is one of the most established label free optical
methods, the typical setup of which is a thin film of gold on a
glass prism, with the receptors bound to the gold surface at the
interface with a solution flowing on top of it and containing the
analyte. Surface plasmons are collective oscillations of free elec-
tron density at the surface of a metal. SPR occurs when surface
plasmons are excited by polarized light at the angle of total in-
ternal reflection, generating an evanescent wave.[46] The angle of
total internal reflection is dependent on the refractive index of the
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Figure 3. Optical based devices for cytokines sensors. a) Nanoplasmonic device integrated with microfluidics with an electroosmotic effect to achieve
fast and sensitive detection. Reproduced with permission.[54] Copyright 2017, American Chemical Society. b) Nanoplasmonic fiber for cytokine detection,
based on an electronic readout signal. Reproduced with permission.[55] Copyright 2017, American Chemical Society.
medium at the metal/solution interface within up to 300 nm far
from the surface (corresponding to the penetration of the evanes-
cent field into the dielectric) and can therefore be affected by
binding of the target to the surface-immobilized binders (Abs,
aptamers) and more generally by the amount of mass adsorbed
on the surface.[47]
In recent years, optical cytokine biosensors were demonstrated
based on plasmonic nanobiosensors, which rely on localized sur-
face plasmon resonance (LSPR) that takes place when conduc-
tion band electrons of nanometer-sized objects (e.g., a nanoparti-
cle, whose dimensions are comparable to the wavelength of light)
participate in the collective oscillations. Excellent reviews on
LSPR-based biosensors have been published.[48,49] Nanobiosen-
sors take advantage of the dramatic improvements in nanofab-
rication of the last decades to overcome some of the limitations
imposed by traditional SPR, such as the complex prism-coupling
instrumentation, which hampers multiplexing and miniaturiza-
tion, and the fact that penetration depth of the evanescent wave
is much larger than average size of target molecules, thus af-
fecting the sensitivity of traditional SPR.[50] As cytokines are rel-
atively small proteins, nanophotonic biosensors have proven to
be highly effective in their detection, allowing detection of mul-
tiple cytokines on a microarray chip functionalized with differ-
ent Abs[42] and enabling the integration of cell culture modules
to achieve real-time analysis (in particular, detection of vascu-
lar endothelial growth factor (VEGF) of live cancer cells[51]) and
even reaching down to monitoring of IL-2 secretion from a single
cell.[51–53] Further recent examples of nanostructured cytokine as-
says involve the integration of optical and electrical components.
This is the case of the IL-1𝛽 biosensor composed by nanoplas-
monic unit integrated with microelectrodes and microfluidics de-
veloped by Song et al. The electrodes present in the sensor are
producing an electroosmotic effect in the electrolyte: the electro-
hydrodynamic agitation enhances the performance of the sen-
sor both in terms of response time (5–15 min) and high sensi-
tivity (1 pg mL−1) of cytokine detection in diluted human serum
(Figure 3a).[54] Cai et al. integrated molybdenum disulfide (MoS2)
photoconductive component with a nanoplasmonic optical filter
that tunes the incident light delivered to the photoconductive
layer through the binding of the analyte (IL-1𝛽) to anti IL-1𝛽-
conjugated gold nanoparticles thus inducing LSPR shifts (Fig-
ure 3b).[55] Other cytokine sensors based on optical transducers
are taking advantage of the quantum dots properties, connected
with aptamers for the detection of TNF-𝛼.[56]
2.2. Electrochemical Biosensors
These devices measure changes of an electrical signal due to the
binding event of the analyte to the corresponding biorecognition
element. The electrical signal can be processed as different mea-
sured parameters such as current, potential, or impedance.[34] Cy-
tokines are not electrochemically active: therefore, they can be in-
directly quantified using electrochemical means by monitoring
the change in the response of a redox probe in solution (typi-
cally, potassium ferri/ferrocyanide couple) upon binding of the
target to the working electrode modified with a specific binder
(for a comprehensive overview of cytokine detection with elec-
trochemical biosensors see review from Dutta et al.[57]). Electro-
chemical impedance spectroscopy (EIS) is by far the most widely
employed electrochemical method for cytokine and chemokine
detection: EIS-based biosensors have been demonstrated for IL-
6,[58,59] IL-8,[60,61] IL1𝛼,[62,63] TNF-𝛼,[64,65] IFN-𝛾 ,[66,67] and TGF-
𝛽.[68] Within this pool of biosensors, one can identify at least three
different materials strategies that have been pursued to enhance
the biosensor performances always using the same transduction
principle.
The first possibility is to test different biorecognition elements:
while Abs have been often preferred,[61–68] a non-Ab scaffold
protein[60] as well as a DNA aptamer[58,59] were also employed to
detect IL-8 and IL-6, respectively. In the former case, the capture
protein based on the cystatin scaffold guaranteed high selectiv-
ity, a remarkably low LOD (90 fg mL−1, ≈8 × 10−15 m) and wide
dynamic range spanning six orders of magnitude.[60]
A second strategy consists in enhancing the active surface
area of the working electrode through functionalization with
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Figure 4. Electrochemical- and field effect transistor-based biosensors for cytokine detection. a) Aerosol-jet printed graphene immunosensors for IFN
and IL-10. Reproduced with permission.[69] Copyright 2020, American Chemical Society. b) Ultraflexible and stretchable graphene-FET nanosensor for
TNF-𝛼 detection. Reproduced with permission.[83] Copyright 2019, Wiley.
nanomaterials, as in the case of electrochemical signal ampli-
fication using gold nanoparticles (AuNPs) on glassy carbon or
gold electrode, followed by immobilization of the anti-IL-6 DNA
oligonucleotide as specific probe.[58,59] Other working electrode
modification protocols were developed to functionalize indium
tin oxide (ITO) electrodes with a layer serving as a primer for the
subsequent immobilization of Abs. To this end, ITO electrodes
have been modified with 6-phosphonoexhanoic acid or with
epoxy-substituted polythiophene polymer to further immobilize
anti-IL-8[61] and anti- IL1𝛼[62] Abs, respectively. In both cases,
the modified ITO surfaces were used as working electrodes in
impedimetric detection with remarkably low LODs (6 and 3.4
fg mL−1, respectively).
A third way to modulate the device response, and in partic-
ular its sensitivity, is to use dedicated materials for signal am-
plification. This strategy was pursued to enhance the conductiv-
ity of ITO electrodes in two different ways. In one case, by first
electrodepositing a reduced graphene oxide layer (rGO) followed
by immobilization of AuNPs, which served as a substrate for
anti-TNF-𝛼 Abs.[64] Alternatively, through modification with car-
bon black[63] mixed with polyvinylidene fluoride and poly(glycidyl
methacrylate) (LP(GMA)), yielding the combined effect of both
increasing the electrochemical signal and providing, through the
epoxy groups of GMA, a tethering point for anti-IL1𝛼 Abs im-
mobilization. Along the same line, an increase in conductivity of
graphene electrodes on a paper substrate was achieved by deposi-
tion of polyaniline, whose amino groups have been further used
to immobilize anti-INF-𝛾 Abs.[66] Importantly, recent advances
in impedimetric detection of cytokines were aimed at demon-
strating devices fabricated by high-throughput methods, such
as aerosol-jet printed graphene immunosensors for interferon-𝛾
(IFN 𝛾) and IL-10[69] or screen-printed gold electrodes for TNF-𝛼
detection (Figure 4).[70]
Besides EIS, other electrochemical methods are amenable for
inflammatory biomarker detection. Differential pulse voltamme-
try (DPV) is a viable alternative: compared to EIS, it allows to fo-
cus only on faradic current contribution, and it does not require
data fitting with equivalent circuit, apart from enabling more
rapid data acquisition. DPV has been employed for detection of
IL-8 upon immobilization of the corresponding Abs on a AuNPs-
rGO composite, which resulted in a reusable and stable (up to
three months) device.[71] DPV was used also as transduction strat-
egy by Russel et al.[72] to sense IL-6, but this time needle-shaped
microelectrodes were used. Interestingly, at variance with what
is typically observed with macro electrodes, the DPV signal was
found to increase with increasing cytokine levels.
As an alternative to immobilization of recognition element
on the working electrode, Arya et al.[73] implemented a so-called
off-surface 2D polycarbonate membrane matrix functionalized
with anti-TNF-𝛼 Abs and located in close proximity of the sen-
sor surface. Sensing was not achieved within a label-free scheme
though but rather as an enzyme labeled immunosensor, namely
by further exploiting a sandwiched assay involving secondary Abs
and alkaline phosphatase to indirectly quantify the target using
DPV.
An elegant solution to achieve electrochemical sensing of cy-
tokines is to use aptamers bearing a redox reporter at one end and
exploiting changes in the aptamer structure triggered by bind-
ing to the analyte to monitor a concentration-dependent change
(typically, a decrease) in the electron transfer between the redox
probe and the electrode. This strategy was pursued, for exam-
ple, to demonstrate IFN−𝛾 and VEGF detection using methylene
blue[74] and ferrocene[75] as redox probes, respectively.
As a general remark, these examples of electrochemical detec-
tion of inflammatory biomarkers operate across several orders of
magnitude spanning the cytokines clinically relevant range and
exhibit low limits of detection. Most notably, apart from validation
in buffered test solutions, most of the above-presented papers
reported on electrochemical detection of inflammatory biomark-
ers in more complex solutions, such as in artificial sweat[59] or
even in real biological samples such as saliva,[61,63,65,71] tears,[70]
and serum.[60–62,64,68] As for the response time, electrochemical
biosensors for inflammatory biomarkers typically exhibited rapid
(within a few minutes) response, as in the case of DPV[71] and
EIS-based[60] IL-8 sensors described above which guarantee a re-
sponse time as low as 9 and 15 min, respectively.
One notable example toward multiplexed detection of cy-
tokines with electrochemical methods involved the use of
Adv. Healthcare Mater. 2021, 2100955 2100955 (6 of 18) © 2021 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH
www.advancedsciencenews.com www.advhealthmat.de
electrically addressable, diazonium modified Abs that could be
immobilized in a controlled way onto multiple Au working elec-
trodes of a fully integrated platform to sense IL-10 and IL-1b via
EIS measurements.[76] Recently, Shen et al. expanded their redox
probe tagged electrochemical aptasensor, described above, into a
multiplexed biosensor for the simultaneous detection of three cy-
tokines (VEGF, IFN-𝛾 , and TNF-𝛼) by immobilizing different ap-
tamers, each bearing a different redox reporter, on a single work-
ing electrode. Changes on the aptamer conformation were trans-
formed into an electrochemical signal due to reduced electron
transfer efficiency between the three redox tags and the electrode,
following analyte binding to the aptamer and unfolding of the
hairpin structure of the latter.[77]
2.3. Field Effect Transistor (FET) Biosensors
In this subsection, we briefly highlight some of the most re-
cently demonstrated label free cytokine biosensors based on
FET devices. We here focus on architectures that could not be
labeled as electrolyte gated organic transistors (EGOTs), that
we thoroughly review in the next sections. The transduction
in FET-based biosensors is typically based on a change in the
drain current upon binding of the target analyte to a specific
biorecognition element immobilized either on the active material
bridging source and drain or (less often) on the gate electrode.
One can further classify FET-based cytokine biosensors with
respect to the active material they employ: within this respect,
nanotubes/nanowires and 2D atomically layered materials are
among the most innovative.
In the former case, real time sensing has been demonstrated
for IL6 with (liquid gated) single-walled carbon nanotubes
(CNT) FETs featuring either aptamer[78] or Abs,[79] invariably
immobilized on the CNTs bridging source and drain using
1-pyrenebutanoic acid succinimidyl ester as linker and by mon-
itoring drain current changes over time upon incubation with
IL6-containing solutions. Alternatively, anti-TNF-𝛼 Abs were
immobilized on the floating gates of a CNT-FET, and the binding
of the cytokine to the gate would induce a field effect on the
underlying CNTs.[80] Silicon nanowires (NWs) have also been
employed in NW-FETcoupled with immunopolymerase chain
reaction,[81], i.e., a sandwiched assay using anti-IL2 Abs followed
by polymerase chain reaction (PCR) amplification, the latter
process detected by the NW-FET as a pH change that could be
related to the IL2 levels in solution.
As for devices based on 2D atomically layered materials, no-
table examples include TNF-𝛼 detection with graphene FET on
flexible[82] and stretchable[83] substrates and real time detection
of the same cytokine with a MoS2 FET.
[84]
The ion-sensitive field-effect transistor architecture has also
been applied to demonstrate IL2 and IL4 biosensors with top-
down fabricated nanoscale devices exhibiting a threshold voltage
shift upon cytokine binding to the corresponding Abs.
2.4. Piezoelectric Biosensors
The transduction principle of these acoustic sensors, which are
devices that are based on the presence of a vibrating element, is
the change in the resonance frequency of a piezoelectric com-
ponent when additional mass is attached to it, typically as a
consequence of (bio)molecular interaction, such as the binding
event between freely diffusing analyte and the biorecognition
element that is immobilized on the piezoelectric element. The
main transducers are quartz crystal microbalances (QCM) and
microcantilevers.[34] The application of this technique to cytokine
detection has been previously reviewed.[85] Bahk et al. improved
the sensitivity of the device by coupling the QCM with magnetic
beads in an immunosandwich-like manner, obtaining a linear dy-
namic range of detection of 40 ng mL−1–2 μg mL−1 of TNF-𝛼, and
relatively short assay time (≈40 min).[86] A recent study used the
same strategy to increase the sensitivity of the technique to detect
TNF-𝛼, reaching a LOD of 1.62 pg mL−1, and a range of detection
spanning 1–1000 pg mL−1, benchmarking their response to the
corresponding results obtained by ELISA. However, this QCM-
based biosensor has a long performance time (>4 h) and uses
magnetic beads to amplify the signal, which could be considered
a kind of label.[87]
2.5. The Road toward Implementation at the Point of Care
ELISA and flow cytometry (e.g., Luminex) are standardized and
well-established methods widely used for clinical detection and
quantification of cytokines. They exhibit high selectivity and sen-
sitivity toward the relevant biomarker, even in complex fluids
such as human serum or cell culture media, and high reliability
and reproducibility—all of which are essential for clinical diagno-
sis. Both methods still require sample processing (label prepara-
tion and incubation), specialized labor, and a significant amount
of time, although in recent years, there has been some progress
in making these technologies automatic and fast. There are vari-
ous requirements for a new biosensor technology to be translated
from the laboratory bench to clinical use—and compete with the
“gold standard” methods. The technology should be amenable
for large scale production, possibly cost-effective and based on
materials with long-term storage stability. The biosensor needs
to be reliable and robust, two essential requirements for clini-
cal tools. Selectivity and sensitivity are also important features,
especially when considering cytokine detection, due to their low
concentrations in body fluids and the sample complexity. Eventu-
ally, the biosensor system should be miniaturized/portable, avoid
complex measurement setups, and thus be easy to use for non-
specialized practitioners. These characteristics are essential not
only for making a biosensor available as a clinical tool in hospi-
tals but also as point-of-care devices for home application or in
field-deployment.
While the biosensor technologies described above have proven
to be innovative and effective, they each exhibit several limi-
tations hindering their usage as clinical tools. Optical sensors
have been implemented with microfluidics and novel fabrica-
tion methods to achieve miniaturized devices. However, opti-
cal sensor limitations are mostly related to the bulky instru-
ments needed for signal readout. For some optical techniques
such as LSPR, the requirement for nanometer-scale features
poses a major hurdle. Piezoelectric-based biosensors on the other
hand require relatively long times for detection. Additionally, de-
spite being in principle a label-free approach, the sensitivity of
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piezoelectric-based sensors has been improved by the use of mag-
netic beads as labels, which then entail all the complications as-
sociated with labeled sensing.
3. Electrolyte-Gated Organic Electronic Transistors
Organic Bioelectronics is rapidly emerging as a leading tech-
nique for biosensing. Organic devices comprising organic
molecules or polymers as active material enable direct commu-
nication between electronics and the biological world.[88] Elec-
tronically and/or ionically conducting organic molecules and
polymers exhibit several advantages compared to their inorganic
counterparts: low temperature processability, flexible substrate
compatibility, large-surface area production, easy microfabrica-
tion methods,[89] and above all, strong ion-pi noncovalent interac-
tions. Some technologies based on organic electronics are already
in commercial use, such as organic light emitted diodes (OLEDs),
while most other stand at the forefront of innovative research ac-
tivities. One device platform is organic transistors, which have
proven to be uniquely amenable to a wide variety of bioelectron-
ics applications[90] spanning the gamut from neural interfaces[91]
to electronically functionalized plants.[92] In particular, organic
electronic transistors represent a versatile and high-performing
platform for the development of novel biosensors.
Organic transistors, like many of their inorganic counterparts,
are devices able to amplify a small variation of potential into a
larger change in current. They are comprised of three electrodes,
generally referred to as source (S), drain (D), and gate (G), us-
ing the terminology of the FET. An organic semiconductor (OSC)
film connects S and D, forming the transistor channel, and G is
connected to the channel through a dielectric material (as in con-
ventional FETs). In the case of EGOTs, an electrolyte serves as
the dielectric between G and the OSC, blocking electronic charge
transport but allowing ions to move freely. Depending on how
ions interact with the OSC, we can define two different kinds
of EGOTs: organic electrochemical transistors (OECTs)[93–97] and
electrolyte gated organic field effect transistors (EGOFETs).[98–100]
In the following subsections, insight into OECT and EGOFET
working principles will be given, respectively. The device physics
of EGOTs, their architectures, as well as a survey on the different
functionalization strategies for biosensing purposes have been
discussed in several reviews[101–106] and the reader can refer to
them for more thorough overviews of the field.
3.1. OECT Device Physics and Working Principle
OECTs operate by VGS-driven changes in the bulk of the ion-
permeable OSC channel. VGS drives ions from the electrolyte
into the permeable polymer, thereby modulating its conduc-
tivity by (de)doping and thus affecting the current flow (IDS)
(Figure 5). In the early 1980s, Wrighton et al. developed the
first OECT, using polypyrrole as channel material.[93] The OECT
concept lay dormant for some time until Andersson et al.
demonstrated[94] the first OECTs based on the then-new ma-
terial poly(3,4-ethylenedioxythiophene) doped with the polyan-
ion polystyrene sulfonate (PEDOT:PSS).[107] This demonstration
foreshadowed some of the utility and versatility of OECTs as
Figure 5. Electrolyte-gated organic transistors. Left) Schematic represen-
tation of electrolyte gated field-effect transistor (EGOFET), where the or-
ganic semiconductor is impermeable to ions and an electrical double layer
is created at the semiconductor/electrolyte interface. Right) Schematic
representation of an organic electrochemical transistor (OECT), where the
organic semiconductor is permeable to ions and results in a volumetric
capacitance.
even at this early stage, the devices were flexible and printed
on paper. Since then, OECTs—now almost ubiquitously based
on PEDOT:PSS or similar substances—have become a mainstay
of organic electronics, with major efforts spanning from fun-
damental studies of underlying mechanisms,[96,108,109] to novel
materials, to a wide array of applications in electronics and
bioelectronics.[90,97] Recent efforts have also focused on expand-
ing the OSC repertoire used in OECTs. As the majority of OECTs
have been based on the p-type polymer PEDOT:PSS, they are
classed as depletion mode devices, i.e., increasing VGS depletes
the channel of mobile charges and decreases IDS. Stable n-
type OSCs have been trickier to develop, but recent develop-
ment with, e.g., poly(benzimidazobenzophenanthroline)[110] or
naphthalene-1,4,5,8-tetracarboxylic diimide with bithiophene[111]
allow for OECT operation in accumulation mode, i.e., increas-
ing VGS increases the mobile charges in the channel and thereby
increases IDS. OECTs can be described by the Bernards and
Malliaras model, which relies on their similarity with the metal-
oxide-semiconductor field effect transistor.[96] In this model, the
channel current in the steady state behavior is described as fol-
lows for the linear and saturation regimes, respectively



















where IDS is the current in the channel, 𝜇 is the charge mobility in
the semiconductor, and C* the volumetric capacitance. W, d, and
L are the width, thickness, and length of the channel, VGS is the
gate voltage, VDS is the drain voltage, and VT is the threshold volt-
age. The transconductance gm is an important parameter to take
into consideration when optimizing OECT performances. gm is
the derivative of the current in the channel with respect to the
gate voltage and can be calculated from Equations (1) and (2). In
contrast to FETs, in OECTs gm scales with all the geometrical fac-
tors, including the thickness of the channel.[112,113] This behavior
arises from the fact that ionic charges accumulate not only at the
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semiconductor interface but also penetrating the bulk. Charge
mobility 𝜇 and capacitance C* are also material properties that
can be addressed in order to design and optimize the device.[114]
OECTs can be operated either in nonfaradic or faradic mode. The
former is based on capacitive charging of an ionic double layer at
the gate that results in the access of ions of opposite sign in the
bulk of the OSC, changing its conductivity. On the contrary, in
the faradic regime, reduction or oxidation processes at the gate
result in channel (de)doping.[115]
A widely adopted model to account for the detection mech-
anism of an OECT based biosensors in faradic mode was
proposed by Bernards and Malliaras.[116] The model relies on
potential changes at the electrode/electrolyte interface, due to
faradic reactions, thus shifting the effective gate voltage and the
current in the channel. OECTs have largely been preferred as
amperometric biosensors operated in the faradic regime. In the
few examples of OECTs biosensors in the nonfaradic mode, the
transduction mechanism was ascribed to charge variations at
the surface following analyte binding[117] or to limited access of
ions to the OSC resulting from their interaction with a peptide-
containing membrane.[118]
3.2. EGOFET Device Physics and Working Principle
EGOFETs feature OSCs that are (in principle) impermeable to
ions. Thus, an applied potential between G and S (VGS) re-
sults in ions accumulating from the electrolyte both at the
gate/electrolyte and the semiconductor/electrolyte interfaces,
forming high-capacitance electrical double layers (EDLs) that are
capacitively coupled. If a potential difference is applied between
S and D (VDS), the field-induced charge carriers accumulated in
the OSC will result in a current flow (IDS) analogous to inorganic
FETs (Figure 5). A water-gated organic field effect transistor was
first demonstrated in 2010 by Kergoat et al. using rubrene and
poly(3-hexylthiophene) (P3HT) as the OSC.[98] The channel cur-
rent in EGOFETs can also be described by Equations (1) and (2)
for the OECT model, with the main difference concerning the
capacitance C and the thickness d. If for OECTs the capacitance
is described as volumetric capacitance (C*), in the EGOFET ionic
charges from the electrolyte are usually depicted as accumulating
at the semiconductor/electrolyte interface, yielding a capacitance
which is independent from the channel thickness.
The EGOFET detection mechanism relies on changes of the
EDL at the interface between the electrolyte and the surface (gate
electrode or OSC) bearing the biorecognition unit (e.g., antibody,
aptamer): upon binding of the analyte, the surface electrochemi-
cal potential and/or the EDL capacitance is affected. In EGOFET
biosensors the biorecognition element is most often bound to the
gate electrode and the recognition with the analyte, thanks to the
capacitive coupling, results in a change of the potential drop at
the OSC/electrolyte interface affecting the current in the channel;
EGOFETs can therefore be seen as potentiometric biosensors.[119]
One of the main issues in the operation of EGOFETs (and of FET
devices in general) as biosensors is the Debye length, which is
the length scale at which mobile ions screen the surface charge






where ɛ is the dielectric constant, ɛ0 is the vacuum permittivity,
KB is the Boltzmann constant, T is the temperature, I is the ionic
strength of the electrolyte, NA is the Avogadro constant, and e
is the elementary charge.[120] In this respect, various strategies
have been proposed to deal with the issue of the Debye screen-
ing length in FET-based sensors. Earlier work suggested operat-
ing the FET sensors in buffered solutions yielding carefully con-
trolled Debye length that must be large enough to ensure sens-
ing at the device interface but should not be too large as charged
unbound species would not be screened and would contribute to
nonspecific response.[121] This strategy, though, might not always
be viable with complex samples, e.g., human bodily fluids, that
contain biomacromolecules for which structural integrity and re-
tention of activity relies on relatively high ion concentration.[105]
Other strategies have been thoroughly reviewed in recent
works[105,122] and include: modulation of the charged surface mor-
phology; redesign of the measurement scheme, e.g., operation
of the FET devices using alternating current signals rather than
potentiometric direct current operation; including polyelectrolyte
multilayer films in the surface functionalization scheme;[123] us-
ing smaller biorecognition units, e.g., aptamers instead of anti-
bodies, to ensure that the biorecognition event takes place within
the Debye screening length.[105,122] With respect to this last solu-
tion, Nakatsuka et al. have exploited aptamer folding to not only
overcome the Debye screening length issue but also to aid the de-
tection of uncharged targets.[124] Most notably, detection beyond
the Debye length has been demonstrated by Palazzo et al.[120] for
an EGOFET biosensor with a mainly capacitive mechanism of
sensing that is based on the formation of a Donnan equilibrium
that yields an additional capacitance, the effect of which does not
depend on the position where such equilibrium is set. In gen-
eral, although solutions to the issue of detection within or beyond
the Debye screening length have been designed, the molecular
mechanisms that enable detection even in high ionic strength so-
lutions and at relatively large distance from a charged surface are
not fully understood and this hinders the rational design of novel
biosensors.
4. Electrolyte-Gated Organic Transistors as
Biosensors
Compared to other detection technologies, organic transistors
represent an optimal biosensor platform due to their unique
features. Organic transistors are based on OSCs, which can be
stable in liquid/aqueous environments, including physiological
media and bodily fluids.[97] They operate at low voltages (0.1–1 V)
and therefore require relatively low power (micro- to mJ).[125]
Moreover, they can be fabricated onto inexpensive and disposable
substrates such as paper[126] or plastic[127] and with low-cost fab-
rication techniques (spin-coating, spray coating, screen printing,
and inkjet-printing), facilitating scaling up of their manufac-
turing. Organic transistors can be miniaturized and integrated
with microfluidics, making portable bioelectronic devices rel-
atively straightforward to design and prototype. Interestingly,
their fundamental operational principle relies on ion motion,
which is also the physiological mechanism for communication,
making them effectively suitable for bridging electronics to
biology.[88]
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Table 1. A selection of OECT and EGOFET protein sensing demonstrations and their various mechanisms and materials.
Target molecule Functionalized interface Sensing unit Channel material Ref.
OECT for protein detection
Prostate specific agent (PSA) Channel Antibody/AuNPs PEDOT:PSS [117]
Human epidermal growth factor receptor 2 (HER2) Gate electrode Nanoprobes PEDOT:PSS [142]
Immunoglobulin-G (IgG) Gate electrode Antibody PEDOT:PSS [143]
Interleukin 6 (IL6) Gate electrode Antibody PEDOT:PSS [144]
l-histidine, l-tryptophan Gate electrode MIPs PEDOT:PSS [147,148]
𝛽-Amyloids Channel Nanoporous membrane PEDOT:PSS [118]
Spike proteins (SARS) Gate electrode Nanobody p(g0T2-g6T2) [149]
Caspase-3 Gate electrode Peptide PEDOT:PSS [150]
EGOFET for protein detection
Interleukin 4 (IL-4) Gate electrode Antibody Pentacene [156]
Interleukin 6 (IL-6) Gate electrode Antibody/aptamer Pentacene [151]
Tumor necrosis factor-𝛼 (TNF-𝛼) Gate electrode Antibody Pentacene [157]
Tumor necrosis factor-𝛼 (TNF-𝛼) Gate electrode Aptamer Pentacene [152]
C-reactive protein (CRP) Gate electrode/SAM Antibody P3HT [159]
C-reactive protein (CRP) Channel Antibody P3HT [120,154]
Procalcitonin (PCT) Channel Antibody P3HT [155]
Vascular endothelial growth factor (VEGF) Gate electrode Aptamer hydrogel DPP-DTT [153]
Ricin Floating gate Aptamer P3HT [174]
In the last decade, EGOTs, both in OECT and EGOFET config-
urations, have been extensively used as biosensors. Such appli-
cations are reviewed in refs. [88,90,97,128], and [129]. Here, we focus
exclusively on their use for sensing inflammatory biomarkers—
or soluble proteins of comparable size, as they pose similar chal-
lenges to sensor design and could therefore be readily adapted
to sense cytokines or other inflammation-related biomacro-
molecules.
4.1. OECT-Based Sensors
OECT-based sensors have mostly been used to record elec-
trophysiological signals (e.g., electroencephalogram and
electrocardiogram)[130–132] or for detection of metabolites through
enzymatic reactions.[111,133–139] Nevertheless, nonenzymatic de-
tection with OECTs, as in the case of immunobiosensors, has
been demonstrated. To this end, Abs,[117] aptamers,[140] and
molecularly imprinted polymers (MIPs)[141] have been used
as specific biorecognition elements (Table 1). One of the first
attempts to develop an Ab-based biosensor exploiting the OECT
architecture was demonstrated by Kim et al., reporting the
detection of prostate specific agent (PSA) in complex with
the inflammation biomarker 1-antichymotrypsin (ACT) with
a sandwich-type structure[117] (Figure 6b). Monoclonal anti-
PSA Abs (PSA mAbs) were immobilized on the PEDOT:PSS
channel, which was functionalized with covalently bound
crown-ether-terminated linkers. The crown-ethers provided
tight host–guest interactions with the surface-exposed amine
groups of PSA mAbs. Binding of PSA-ACT complexes to the
mAbs-functionalized channel led to a [PSA-ACT]-dependent in-
crease of the drain current that the authors rationalized in terms
of an increase of the negative surface charge, due to the PSA
isoelectric point of 6.9. The increased negative surface charge, in
turn, decreased the dedoping effect of the gate voltage and hence
lowered the charge-carrier depletion. Further sandwiching of
the mAb-bound PSA-ACT complex with polyclonal anti-PSA
Abs conjugated with Au nanoparticles improved the biosensor
performance, yielding both a wider dynamic range and lower
PSA LOD down to 1 pg mL−1 (Figure 5b).
Sandwiched modification of the sensing interface was also ap-
plied by Fu et al. to demonstrate an OECT-based biosensor for
human epidermal growth factor receptor 2 (HER2), a breast can-
cer treatment biomarker.[142] Despite being an immunosensor,
the sensing principle in this case relied on faradic operation of
the OECT with the aim of enhancing sensitivity with respect to
nonfaradic mode. Nonfaradic mode corresponds to operation of
the OECTs as a potentiometric FET governed by capacitive cou-
pling. Here, monoclonal anti-HER2 Abs was immobilized on the
gate. When HER2 was captured by this surface-bound recog-
nition layer, it promoted further binding of gold nanoparticles
(AuNPs) with both anti-HER2 Abs and horseradish peroxidase
(HRP) immobilized on them. The surface concentration of HRP
was thus directly proportional to that of HER2. HRP is a redox
enzyme that catalyzes oxidation of hydrogen peroxide to water,
and in this case led to a faradic decrease of the channel current.
The authors interpreted the [HER2]-dependent response in terms
of shift of the effective gate voltage, following the widely used
Bernards model,[96] and the biosensor performance was remark-
able both in terms of LOD (as low as 10−14 g mL−1) and linear
response up to 10−7 g mL−1.
Ultralow limit of detection (6 × 10−15 m) with an OECT-based
biosensor operated in nonfaradic mode was achieved by Mac-
chia et al., who demonstrated an immunoglobulin-G (IgG) im-
munosensor by functionalizing the gold gate electrode with spe-
cific anti-IgG Abs.[143] The concentration-dependent change in
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Figure 6. OECT for protein detection. a) PEDOT:PSS based OECT for detection of IL-6, integrated with an immune-affinity membrane incubation steps to
increase the analyte concentration. Reproduced with permission.[144] Copyright 2018, Royal Society of Chemistry. b) OECT immunosensor for detection
of PSA with gold particle signal amplification. Reproduced with permission.[117] Copyright 2010, Elsevier.
the channel current occurs in a range from 6 × 10−15 to 60 ×
10−12 m range and was attributed to a shift of the surface poten-
tial following the biorecognition process.
To date, and to the best of our knowledge, only two examples
of OECT-based sensors for cytokine detection have been demon-
strated. Gentili et al. reported specific IL-6 detection via recogni-
tion by anti-IL-6 Abs immobilized on the gate, integrated with an
immune-affinity membrane to pre-concentrate the analyte in the
sample, allowing detection of [IL-6] as low as 2 ng mL−1 (90 ×
10−12 m).[144] IL-6 binding to the sensing moiety altered the EDL
capacitance, affecting channel current modulation by the gate
electrode (Figure 6a). Decataldo et al. opted for stepwise func-
tionalization of plasma-treated PEDOT:PSS channels modified
with (3-Aminopropyl)triethoxysilane (APTES) followed by immo-
bilization of target-specific Abs using biotin/streptavidin cou-
pling for sensing the growth factor cytokine bone morphogenic
protein 2[145] down to 1.6 pg mL−1.[146]
Although Abs are by far the most widely exploited biorecog-
nition unit for protein detection, MIPs represent a promising
alternative. MIPs can be synthesized with different techniques,
but they are invariably characterized by the presence of cavities
that are complementary in terms of size, shape, and chemical
functionality to the target molecule. The selectivity that can be
achieved with MIPs can be extremely high, as demonstrated by
Zhang et al., who developed OECT biosensors with electrode-
posited MIP-functionalized gates for chiral recognition of enan-
tiomers of tryptophan and tyrosine [147] and histidine.[148] The
mechanism behind this amino acid sensing could not be ex-
tended to electrochemically inactive molecules as it requires ox-
idation of the MIP-allowed substances at the gate, i.e., faradic
sensing. Nevertheless, the integration of MIPs at relevant OECT
interfaces is viable for detection of larger molecules such as oligo-
and polypeptides, for which specific recognition by ad hoc syn-
thesized polymers was demonstrated. Along this track, Wustoni
et al. demonstrated a MIP-based OECT biosensor for in vitro de-
tection of A𝛽 aggregates associated with Alzheimer’s disease.[118]
The working mechanism was based on ion permeability through
a nanoporous modified membrane on top of the channel: the
membrane was functionalized with molecules able to bind A𝛽
aggregates and thereby blocking ions from reaching the channel,
resulting in a current modulation proportional to the aggregate
concentration.
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Motivated by the recent pandemic, Guo et al. developed a
nanobody-based OECT for fast and specific detection of SARS-
CoV-1/2, and Middle East respiratory syndrome coronavirus
(MERS-CoV) antigen spike proteins. The functionalization pro-
cedure was performed on the gold gate electrode and followed
two steps: a) formation of a self-assembled monolayer (SAM)
and b) incubation with a nanobody-SpyCatcher fusion protein
against spike proteins. The OECT sensor was able to detect the
specific antigen in complex media in attomolar concentration
range, offering a point-of-care platform for virus detection.[149]
Yu et al. demonstrated an OECT-based biosensor for the detec-
tion of caspase-3, a proteolytic enzyme involved in apoptotic pro-
cesses. Their approach was based on measuring the activity of
the caspase-3 on a peptide-modified gold gate electrode. The de-
tection mechanism relied on surface potential changes related to
the amount of peptide bound at the gate electrode. The device
was used to study the apoptotic process in HeLa cell culture, pro-
viding a facile and sensitive approach for the study of proteolytic
enzymes.[150]
4.2. EGOFET-Based Sensors
EGOFETs have more frequently been preferred for the detection
of electrochemically inactive analytes, as is the case of many pro-
teins. As described in the previous section, the detection mecha-
nism underlying EGOFET biosensors involves modification of
the EDL at the gate/electrolyte or channel/electrolyte interface
upon the specific biorecognition event. Due to well-established
protocols for biomolecule immobilization on bare or modified
metal surfaces (primarily gold), the most common approach for
biosensing with EGOFETs relies on Ab attachment to a gold
gate. The use of aptamers instead of Abs [151–153] or the con-
finement of the biorecognition unit at the channel/electrolyte
interface[120,154,155] are less common (Table 1).
EGOFETs were first used for sensing cytokines, specifically
interleukin 4 (IL-4), by Casalini et al.[156] Two strategies for
confinement of anti-IL-4 Abs at the Au gate/electrolyte inter-
face were compared: i) covalent attachment of the Abs to a
6-aminohexanethiol (HSC6NH2) SAM through glutaraldehyde
crosslinking and ii) noncovalent, though selective, interaction of
the Abs with a (sub)monolayer of Protein G, bound to the gate
via an N-terminal hexahistidine tag. Although both approaches
result into gate-immobilized anti-IL-4 Abs, the second protocol,
which should yield more uniformly oriented Abs with respect to
the SAM-based approach, was found to be more effective for cy-
tokine. The difference was ascribed to higher probability of spe-
cific binding events, based on single molecule force spectroscopy
approaches. Along this line, Diacci et al. demonstrated EGOFET
biosensors for a second cytokine, IL-6, by gating the device with
Au electrodes functionalized either with the above described Pro-
teinG/Ab approach, or using a smaller (≈100 amino acid) peptide
aptamer bound directly to gold via a polyhistidine tag in a sin-
gle step approach.[151] The two approaches (full Ab and aptamer)
likely yielded different surface concentrations of the biorecogni-
tion unit as well as binding events taking place at different dis-
tances from the Au surface. However, both biosensors exhibit
dynamic ranges spanning four orders of magnitude (pm and
low-nm regime) and LODs as low as 1 × 10−12 m. These LODs
are comparable to serum levels under physiological conditions,
meaning that these biosensors could potentially be used to mon-
itor patients suffering from inflammatory response to various
pathologies.
EGOFETs were also demonstrated as biosensors toward an-
other cytokine, TNF-𝛼, by Berto et al., again using either
ProteinG-bound Abs[157] or peptide aptamers[152] to selectively
bind the pleiotropic cytokine. In the first case, the immunosen-
sor was integrated in a polydimethylsiloxane microfluidic system
and could detect TNF-𝛼 down to 100 × 10−12 m (Figure 7a). The
operability in more complex samples was assessed by detecting
TNF-𝛼 released into cell culture medium by human monocytes
in vitro. The authors explained the device sensitivity in terms of
the density of states (DOS) of the organic semiconductor used
(pentacene), ascribing the large variations of the device response
to shifts of the Fermi level in the (super-exponential) tail of the
DOS. The later work by Berto et al. reported on a peptide aptasen-
sor for TNF-𝛼, reaching a LOD as low as 1 × 10−12 m even in cell
culture media containing 10% fetal bovine serum.[152] Parkula et
al. in 2020 presented a novel lab-on-a-chip integrating a microflu-
idic system with an EGOFET device. The device features four
gate electrodes, three of which are functionalized with a peptide
aptamer specific toward TNF-𝛼. The fourth electrode is covered
only by a self-assembly monolayer (SAM) with no biorecognition
elements, thus serving as an internal control on potentially inter-
fering nonspecific binding and/or on current changes caused by
external factors, such as bias stress. This setup provides measure-
ments in triplicate, thus enabling a check on the reproducibility
of the biosensor response. Moreover, the EGOFET shows high
selectivity and a detection limit as low as 3 × 10−12 m.[158] This
example shows how EGOFET biosensors are suitable for minia-
turization and integration with microfluidic system.
The biorecognition moiety can also be confined at the inter-
face between the organic semiconductor and the electrolyte, to
sense protein targets freely diffusing in solution as demonstrated
by Magliulo et al.,[154] Palazzo et al.,[120] and Seshadri et al.[155]
In the former work, anti-CRP Abs were physisorbed on a P3HT
film bridging source and drain and a nonionic hydrophilic poly-
mer (N-[tris(hydroxy- methyl)methyl]acrylamide-lipoic acid con-
jugate, pTHMMAA) was used as a blocking agent to minimize
nonspecific adsorption on the device channel. Binding of CRP
to the corresponding Abs at the P3HT surface caused a decrease
of the drain current that was tentatively ascribed to changes in
the gating capacitance upon analyte immobilization at the chan-
nel/electrolyte interface. Simplicity and time-effectiveness of the
functionalization strategy were among the main features of the
proposed device, which reached a LOD corresponding to 2 ×
10−12 m was estimated, with the biosensor working in a dy-
namic range spanning five orders of magnitude.[154] This repre-
sented a substantial advancement with respect to the phospho-
lipid combined with streptavidin or avidin monolayer cast on
P3HT OSC, by the same authors.[120] A few years later, a similar
strategy was exploited to sense procalcitonin (PCT), which may
serve as a sepsis marker, down to the pm regime and spanning
physiologically relevant ranges. Anti-PCT Abs were again physi-
cally adsorbed on a P3HT film surface, but instead of choosing
pTHMMAA as blocking agent, the authors used bovine serum
albumin (BSA). At variance with what was observed for CRP
detection, where the transconductance was mostly affected by
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Figure 7. EGOFET for protein detection. a) Microfluidic integrated EGOFET immunosensor for the detection of TNF-𝛼. Reproduced with permission.[157]
Copyright 2016, American Chemical Society. b) EGOFET based immunosensor for single protein detection. Reproduced with permission.[161] Copyright
2018, Springer Nature.
the biorecognition event, the drain current decrease following
PCT binding is mainly contributed by changes in the thresh-
old voltage that could be ascribed to the negative charge of PCT
at the operational pH, which would act as trap sites for the
(hole) charge carriers.[155] Recently, Torsi’s group demonstrated
EGOFET-based biosensors reaching the ultimate sensitivity of
single molecule detection (hence the acronym SiMoT to identify
their device architecture) (Figure 7b). The key ingredient to the
ultralow LOD is a millimeter-sized gold lamina functionalized
with a mixed 3-mercaptopropionic acid (3-MPA): mercaptounde-
canoic acid (MUA) SAM. MUA enables covalent immobilization
of trillions of capturing proteins (followed by further blocking
with BSA) while MPA forms a H-bonding network that cooper-
atively rearranges upon analyte binding, thus causing a shift of
the work function of the gate electrode. The remarkable 1(±1)
molecules LOD has been achieved for different targets, includ-
ing CRP[159] and IgM and IgG.[160,161] Pallu et al. used a differ-
ent approach by showing a proof of concept for DNA hydrogels
to be used for detection of VEGF. The authors chose to intro-
duce a hydrogel to exploit its ability to change its 3D structure
upon target binding as an attempt to overcome traditional lim-
itations set by the Debye length in common buffer solutions at
the gate/electrolyte interface. The DNA hydrogel could then gate
an EGOT and, by incorporating a VEGF-specific aptamer within
the hydrogel, the presence of the growth factor in the electrolyte
surrounding the hydrogel could be detected.[153]
Many of the examples reviewed in the present section are
demonstrations of biosensors in buffered spiked solutions of
the relevant cytokine. The translation to complex fluids such
as plasma, serum, or saliva poses a significant challenge to the
design of EGOT-based biosensors since, in the “traditional”
layout, two interfaces are simultaneously exposed to the sample,
i.e., both the gate and the OSC film, and therefore both might
represent adsorption sites for interfering species. Avoiding
nonspecific binding at the sensing interface is particularly
challenging for label-free biosensors. The main strategies used
for this purpose are focused on adding blocking agents (e.g.,
BSA[117,142,143,151,152,155,159]) or by surface chemistry (e.g., oly-
goethyleneglycol sub-monolayers[144,154,159]), in order to fill the
nonfunctionalized spots between the surface-tethered specific
biorecognition elements. A third approach would be sample
pre-treatment, although it is not recommended for biomark-
ers with low physiological/pathological concentrations.[162,163]
Extended/floating gate is an elegant and effective solution to
the problem[164] that avoids the contact between the sample
and the OSC, therefore limiting the problem of nonspecific
adsorption to the gate surface only and basically deconstruct-
ing the traditional EGOT architecture into two parts, namely
the transistor and the sensing chamber. In the extended gate
configuration, the transistor is separated by a dielectric (ion gel
or electrolyte solution in the case of EGOTs) from the first arm
of a gate electrode that extends (hence the name) far from it
with a second (sensing) arm functionalized with the recognition
element that reaches a physically distinct reservoir containing
the sample. The potential of the extended gate is not controlled
directly (thus the devices are consequently termed as “floating”)
by the gate voltage, which is instead imposed between the source
and a second electrode, and capacitively coupled to the sensing
arm through the sample. Extended gate OFETs were reported
for IgG,[165,166] IgA,[167] human glycoprotein,[168] histidine-rich
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protein (albumin),[169] histamine,[170] phosphorprotein,[171]
CRP,[172] and glutathione[173] sensing. Other notable examples
of applications that provide evidence for effective sensing in
real-life scenarios are CRP sensors integrated with a smart
surgical catheter[172] and a floating gate EGOT for aptamer-based
detection of ricin in complex food matrices like milk or orange
juice.[174] Despite falling outside the focus of this paper, it is
worth mentioning that EGOFETs have also been demonstrated
as biosensors for other protein biomarkers, e.g., antidrug
Abs,[175] immunoglobulin,[160,176] protein aggregates,[177] vi-
ral proteins,[178,179] alpha-fetoprotein,[180] and myelin basic
protein.[181]
5. Outlook
Inflammatory processes are driven and regulated by networks of
multiple cytokines and different relative levels between these pro-
teins are responsible for different pathological states. Deeper un-
derstanding of inflammatory pathologies will thus require devel-
opment of (ideally miniaturized) sensors able to simultaneously
analyze multiple markers in the same sample. In addition to the
ability to identify the “cytokine fingerprint” of various patholo-
gies, these sensors will require only minimal sample quantities
for the single analysis, rather than collection of multiple samples
for individual detection of each cytokine. Multifunctionality will
also lead directly to more simple systems at the point-of-care as
well as lower power requirements, higher-throughput manufac-
turing, and likely lower cost to healthcare providers and patients.
To date, only a few researchers have taken up the challenge to
demonstrate such detection of multiple cytokines.[42,76,182–184] We
believe that OECTs and EGOFETs are suitable platforms to build
these next-generation multifunctional sensors as they can com-
bine optimal LOD, ease of manufacture, and ease of integration
with other (bio)electronic systems and therapies.
In regard to therapeutic approaches, inflammatory diseases
are traditionally treated by (local or systemic) administration
of anti-inflammatory drugs.[185] More recent treatment meth-
ods have also used electrical stimulation, primarily of the va-
gus nerve, to mediate inflammatory responses.[186–188] Traditional
drug delivery methods, such as injections or oral administra-
tion, are well known procedures with systemic effects on the
body. However, these methods present numerous drawbacks
since they act on multiple pathways simultaneously, effect re-
gions outside of the primary inflammation zone, and thus have
the potential to cause mild to severe side effects.[189] Continu-
ous monitoring of inflammation markers coupled with an auto-
matic drug delivery system may reduce the amount of molecules
used and give a personalized treatment to reduce side effects.[188]
The very same organic electronic materials, methods, and con-
cepts applied in the development of OECTs and EGOFETs have
been used for a variety of such drug delivery systems, including
controlled release electrodes, electrophoretic transport through
ion exchange membranes, and even micromechanical delivery
systems.[88,190] Likewise, recent developments in “electroceutical”
treatment of inflammatory disorders have also turned to organic
electronics.[191,192] In these systems, electronic signals are deliv-
ered locally—most frequently to the vagus nerve—to modulate
downstream inflammatory responses.
The parity of fabrication techniques, materials, and operat-
ing conditions make the integration of cytokine sensing OECTs
and EGOFETs with organic electronic delivery technologies and
“electroceuticals” fairly straightforward and thus a promising
path toward personalized treatment systems. However, in ad-
dition to the challenges of development and optimization of
the pharmaceutical and electrical actuators in such systems, the
OECT and EGOFET sensors will require standardization and en-
hanced reliability before they can be implemented at the PoC.
This is of course a major focus of the research community. The
authors of this Progress Report have recently spearheaded the
Marie Skłodowska Curie European Training Network BORGES
(Biosensing with Organic Electronics)[193] to specifically inves-
tigate the underlying mechanisms of OECT and EGOFET sen-
sors with the ultimate aim of providing more standard protocols
for their use in clinical settings. The project spans fundamen-
tal academic research, to industry expertise in instrumentation
and modeling, to pre-clinical expertise close to the point-of-care.
Of course, there are many challenges in reaching the aims of the
BORGES project, and indeed the goals of the OECT and EGOFET
biosensor community in general: miniaturization will require
iterated steps of optimization and testing; reliably introducing
samples at the point-of-care will require further integration with,
e.g., fluidic systems; and achieving low-cost high-throughput
manufacturing will require a great deal of development effort to
translate microfabrication techniques to, e.g., printing methods.
Ultimately, we aim to provide the scientific and healthcare com-
munities with a suite of sensor technologies that are robust, mul-
tifunctional, and certified for use with human patients.
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